News

Company News: ISA Pharmaceuticals Establishes Advisory Board

– Renowned Specialists to Support Development of ISA’s Advancing Pipeline –

ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, today announced the establishment of an advisory board of seasoned executives and scientists. Five world-renowned specialists will bring strong clinical, regulatory, scientific and business expertise to assist ISA in developing and implementing its corporate and R&D strategy.

The members of ISA’s advisory board are:

Alex Eggermont, M.D., Ph.D., is General Director of the Institut de Cancérologie Gustave Roussy (IGR, Villejuif) and a Professor of Surgical Oncology at Rotterdam’s Erasmus University (Netherlands). Prof. Eggermont specializes in preclinical and clinical / translational oncology, and is a specialist in immunotherapy research and the treatment of melanomas and sarcomas.

Ulrich Granzer, Ph.D., is a pharmacist and founder of Granzer Regulatory Consulting & Services. In addition, he is a founding member and President of the Board of the German Association of Regulatory Affairs (DGRA). He has long-standing experience in all regulatory aspects of the pharmaceutical industry from his time at Glaxo (now GSK), BASF, Pharma / Knoll, and Bayer. At Bayer, as Vice President of Global Regulatory Affairs he was responsible for all regulatory aspects of the development and submission of projects worldwide. Dr. Granzer’s expertise in regulatory affairs extends to both U.S. (FDA) and European (EMA) regulatory authorities.

Drew M. Pardoll, M.D., Ph.D., is a cancer immunologist and an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine. He is also Director of Cancer Immunology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Pardoll specializes in cancer immunology and cancer immunotherapy and has contributed to the development of many immunotherapies.

Sjoerd H. van der Burg, Ph.D., is a Professor in Experimental Cancer Immunology and Therapy at the Department of Clinical Oncology of the Leiden University Medical Center. He has extensive experience in tumor immunology and the immunotherapy of cancer, in particular the development of therapeutic vaccine strategies and the adoptive transfer of ex-vivo expanded T cells. He is specialized in the immunomonitoring of human T cell responses and is the current Chair of the Association for Cancer Immunotherapy Immunoguiding Program (CIP).

Mark Krul, Ph.D., is a co-founder of ISA Pharmaceuticals and a co-founder and Managing Partner at Aglaia BioMedical Ventures, a Dutch venture firm focusing on oncology. He is a molecular biologist and immunologist with over 20 years of experience in anti-cancer drug development, among others as a Research Manager at the European Cancer Center and as Head of the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection in the Netherlands. Mark Krul has a strong track record in founding, managing and financing early-stage oncology companies. Mark Krul will chair ISA’s advisory board.